A. Brunot

发表

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2017, Targeted Oncology.

Therapeutic innovations in breast cancer.

V. Diéras, A. Brunot, C. Perrin, 2019, Presse medicale.

Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib’s Toxicities in Hepatocellular Carcinoma

A. Guillygomarc’h, A. Brunot, B. Laguerre, 2017, Cancer nursing.

Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients

V. Diéras, V. Quillien, A. Brunot, 2021, Scientific Reports.

Independent association of PD‐L1 expression with noninactivated VHL clear cell renal cell carcinoma—A finding with therapeutic potential

K. Bensalah, N. Rioux-Leclercq, J. Patard, 2017, International journal of cancer.

58P Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients

V. Quillien, J. Corne, A. Brunot, 2020 .

Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up.

K. Bensalah, N. Rioux-Leclercq, J. Patard, 2016, European urology focus.

Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients.

K. Bensalah, N. Rioux-Leclercq, A. Lardenois, 2023, European urology.

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2019, Clinical genitourinary cancer.

Implications of BRCA Germline Mutations on Breast Cancer Medical Treatment

V. Diéras, A. Brunot, T. Motte rouge, 2020, Current Breast Cancer Reports.

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.

J. Grob, C. Lebbé, S. Prey, 2020, JAMA dermatology.

Impact of EPclin on adjuvant therapeutic decision making and comparison of EPclin to the PREDICT tool

V. Diéras, V. Quillien, V. Lavoué, 2021, The International journal of biological markers.

Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study

K. Bensalah, N. Rioux-Leclercq, A. Lespagnol, 2021, Journal of Clinical Pathology.

Hepatocellular carcinoma in elderly patients: challenges and solutions

A. Brunot, M. Pracht, J. Edeline, 2016, Journal of hepatocellular carcinoma.

Synchronous Metastatic Clear‐Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype

K. Bensalah, N. Rioux-Leclercq, J. Mosser, 2017, Clinical genitourinary cancer.

PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2015 .

Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.

F. Bidard, V. Diéras, V. Quillien, 2023, Clinica chimica acta; international journal of clinical chemistry.

Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors

A. Guillygomarc’h, M. Latournerie, A. Brunot, 2014, Cancer Chemotherapy and Pharmacology.

Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2017, Urologic oncology.